#ranibizumab

[coherentmicom]

https://hallbook.com.br/blogs/848554/Diabetic-Macular-Edema-Market-Growth-Driven-by-Innovative-Therapeutics

[coherentmicom]

https://hallbook.com.br/blogs/748570/Diabetic-Macular-Edema-Market-Growth-Driven-by-Innovative-Therapies

[prateekcmi]

Lucentis Market Outlook And Strategic Growth Analysis

The Lucentis Market is undergoing significant contraction driven by emerging biosimilars and evolving pricing frameworks. While initial uptake for neovascular age-related macular degeneration was robust in 2024, 2025 forecasts from comprehensive market analysis highlight an industry pivot toward cost optimization, novel delivery systems, and broader digital therapeutics. These shifts align with broader industry trends toward biosimilar adoption and integrated patient support solutions.

Get More Insights on Lucentis Market https://prateikcmi.livepositively.com/lucentis-market-analysis-size-trends-and-forecast-insights/new=1  

[bookpiofficial]

A Review of the Use of Anti-vascular Endothelial Growth Factor Drugs at the Eye Foundation Centre for the Prevention of Blindness, Nigeria | Chapter 06 | New Insights into Disease and Pathogen Research Vol. 3

Aims: To describe the sociodemographic details and indications for the use of anti-vascular endothelial growth factor (anti-VEGF) injections at the Eye Foundation Centres in Nigeria.

Study Design: Retrospective, observational analysis.

Place and Duration of Study: Eye Foundation Hospitals in Lagos, Ijebu-Imushin and Abuja, Nigeria between January 2011 and December 2014.

Methods: Records of all anti-VEGF injections given were assessed. All consecutive cases were taken in proportion seen in the 4 centres. Age, sex, occupation, diagnoses and types of injection were recorded in the data sheet prepared for the study.

Results: This study included 1072 eyes of 540 patients. Mean age was 60.37(12.74) standard deviation years. The age range is from 10 – 92 years. 326(60.4%) males and females 214(39.6%) were seen. Patients that presented were mostly currently employed 40.8%, previously in paid job 25.8% and businessmen and women 24.5%. Total injections were 2443, given during the study period. Anti-VEGF agents used were Bevacizumab (2278; 93.2%) and Ranibizumab (165; 6.8%).

Indications for injection were: proliferative diabetic retinopathy (PDR) 27.4%, retinal vein occlusion (RVO) 17.6% and vitreous haemorrhage (VH) due to proliferative diabetic retinopathy and sickle cell retinopathy 10.6%. There was an association between sex and disease (p < 0.001) and age and disease (p < 0.001).

Conclusion: The use of anti-VEGF injections are on the increase especially bevacizumab. The most common indications are proliferative diabetic retinopathy, retinal vein occlusion and VH. The treatment was done more for males, middle class and the rich.

Author(s) Details

Tayo Julius Bogunjoko Eye Foundation Centre for the Prevention of Blindness, Nigeria.

Dr. Adekunle Hassan, MD. FRCS, FRCOph, FWACS, FNICM Eye Foundation Centre for the Prevention of Blindness, Nigeria.

Dr. Olufemi Oderinlo Eye Foundation Centre for the Prevention of Blindness, Nigeria.

Okonkwo Ogugua Eye Foundation Centre for the Prevention of Blindness, Nigeria.

Mildred Ulaikere Eye Foundation Centre for the Prevention of Blindness, Nigeria.

Toyin Akanbi Eye Foundation Centre for the Prevention of Blindness, Nigeria.

Abimbola Ashaye Eye Foundation Centre for the Prevention of Blindness, Nigeria.

View Books: http://bp.bookpi.org/index.php/bpi/catalog/book/112

[drdanielapetrache]

(via Nou tratament pentru retinopatia diabetica)

Un nou tratament pentru retinopatia diabetica a fost aprobat de FDA sau Food and Drug Administration. Noul tratament pentru retinopatia diabetica poarta numele de Lucentis (ranibizumab).

[globalmedicaldiscovery]

Single- and repeated-dose toxicity study of bevacizumab, ranibizumab, and aflibercept in ARPE-19 cells under normal and oxidative stress conditions

Journal Reference

Biochem Pharmacol. 2016;103:129-39.

Saenz-de-Viteri M1, Fernández-Robredo P2, Hernández M3, Bezunartea J4, Reiter N4, Recalde S2, García-Layana A5.

Show Affiliations

Experimental Ophthalmology Laboratory, School of Medicine, University of Navarra, 1 Irunlarrea Street, 31008 Pamplona, Spain; Department of Ophthalmology, Clínica Universidad de Navarra, School of Medicine, University of Navarra, 36 Pio XII Avenue, 31008 Pamplona, Spain.

Experimental Ophthalmology Laboratory, School of Medicine, University of Navarra, 1 Irunlarrea Street, 31008 Pamplona, Spain; IdiSNA, Navarra Institute for Health Research, 31008 Pamplona, Spain.

Experimental Ophthalmology Laboratory, School of Medicine, University of Navarra, 1 Irunlarrea Street, 31008 Pamplona, Spain; IdiSNA, Navarra Institute for Health Research, 31008 Pamplona, Spain. Electronic address: [email protected].

Experimental Ophthalmology Laboratory, School of Medicine, University of Navarra, 1 Irunlarrea Street, 31008 Pamplona, Spain.

Experimental Ophthalmology Laboratory, School of Medicine, University of Navarra, 1 Irunlarrea Street, 31008 Pamplona, Spain; Department of Ophthalmology, Clínica Universidad de Navarra, School of Medicine, University of Navarra, 36 Pio XII Avenue, 31008 Pamplona, Spain; IdiSNA, Navarra Institute for Health Research, 31008 Pamplona, Spain.

  Abstract

We assessed the effect of single and repeated doses of bevacizumab, ranibizumab, and aflibercept on cell viability, proliferation, permeability, and apoptosis of ARPE-19 cells. MTT and BrdU assays were used to determine viability and proliferation after single or repeated doses of anti-VEGF drugs under  normal and oxidative stress conditions. Caspase-3 expression after single and repeated doses of the 3 drugs was assessed using immunofluorescence. Transepithelial-electrical-resistance (TER) was measured to study the effect of anti-VEGFs on retinal pigment epithelium (RPE) permeability under  normal and  oxidative  stress conditions. Flow cytometry was used to detect intracellular accumulation of the drugs. Finally, a wound healing assay was performed to investigate the effect of the drugs on RPE cell migration. Single and multiple doses of anti-VEGF drugs had no effect on cell viability and proliferation. The oxidative effect of H2O2 decreased cell viability and proliferation; however, no difference was observed between anti-VEGF treatments. Immunofluorescence performed after single and repeated doses of the drugs revealed some caspase-3 expression. Interestingly, anti-VEGFs restored the increased permeability induced by H2O2. The 3 drugs accumulated inside the cells and were detectable 5days after treatment. Finally, none of the drugs affected migration.

In conclusion, no measureable toxic effect was observed after single or repeated doses of VEGF antagonists under normal and oxidative stress. Intracellular accumulation of the drugs does not seem to be toxic or affect cell functions. Our study suggests that anti-VEGFs could have a preventive effect on the maintenance of the RPE barrier under oxidative stress.

Copyright © 2016 Elsevier Inc. All rights reserved.

Go To Biochem Pharmacol

  from Single- and repeated-dose toxicity study of bevacizumab, ranibizumab, and aflibercept in ARPE-19 cells under normal and oxidative stress conditions

[eyethings]

Avastin vs. Lucentis: Treatment of Wet-AMD

For some time now, the pharmaceutical and ophthalmic industries have been keeping a close eye (if I may) on two drugs produced by Genentech/Roche: Avastin (Bevacizumab) and Lucentis (Ranibizumab). Both are humanized monoclonal antibodies derived from mice, and target and inhibit vascular endothelial growth factor A (VEGF-A), and thus inhibit angiogenesis. Avastin is an important drug used in cancer management, targeting blood supply to tumours, and Lucentis is a potent drug used to treat Wet-AMD via intraocular injections. Lucentis, however, is a few hundred times more expensive than Avastin.

A while back, some ophthalmologists figured that since Avastin and Lucentis are nearly identical in terms of their mechanism of action, Avastin should work well for Wet-AMD too... and apparently it did. However, Avastin isn't officially approved for the treatment of Wet-AMD, and Genentech/Roche won't fund clinical trials for the use of Avastin in Wet-AMD, perhaps understandably so, considering the immense cost of research and development of each drug. About 2 years ago, however, a public clinical trial called Comparison of AMD Treatment Trials (CATT) was initiated, and the results of that study have recently been published by the journal, Ophthalmology.

Here's a link to those results (right click, save as).

Basically, the ophthals were right, and there is no real therapeutic advantage of Lucentis over Avastin; both drugs produce the same kind of improvement in visual acuity after the same kind of treatment regime. So, having followed this study for awhile, I guess I'm curious where things go from here: healthcare cover, future drug design strategies, marketing, etc.

Do you think Lucentis will still be used as a treatment option?